Document Detail


Rituximab maintenance versus retreatment in follicular lymphoma.
MedLine Citation:
PMID:  23044794     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Follicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. Although the introduction of the anti-CD20 monoclonal antibody rituximab has represented a major breakthrough, FL remains incurable with standard chemoimmunotherapies. The goals of therapy in symptomatic FL patients include the following: obtaining high response rates, extending the duration of remission, prolongation of survival and improving quality of life, while minimizing adverse events. To extend remission duration and possibly survival outcomes, maintenance therapy with rituximab has been shown to be effective in both frontline and relapsed/refractory settings. However, the optimal timing, schedule and length of maintenance therapy are controversial. Herein, we review the current data for maintenance rituximab in FL, discuss the current controversies for this modality, attempt to define its role relative to the more conservative retreatment approach and provide practical recommendations for its clinical use. Copyright © 2012 John Wiley & Sons, Ltd.
Authors:
Amruth R Palla; Mehdi Hamadani
Related Documents :
15032284 - Diagnostic problems on frozen section examination of myometrial invasion in patients wi...
7960984 - Postoperative high dose-rate intravaginal brachytherapy combined with external irradiat...
14971534 - Accuracy of transvaginal ultrasound for the evaluation of myometrial invasion in endome...
8678154 - Angiogenesis factor in endometrial carcinoma: a new prognostic indicator?
15740494 - Differences in long-term survival after transjugular intrahepatic portosystemic shunt f...
22404484 - Intraluminal high-dose-rate brachytherapy for palliation of dysphagia in cancer of the ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-9
Journal Detail:
Title:  Hematological oncology     Volume:  -     ISSN:  1099-1069     ISO Abbreviation:  Hematol Oncol     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8307268     Medline TA:  Hematol Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 John Wiley & Sons, Ltd.
Affiliation:
Department of Internal Medicine, Danbury Hospital, Danbury, CT, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Optical imaging techniques for point-of-care diagnostics.
Next Document:  Integrated Synthesis of Poly(o-phenylenediamine)-Derived Carbon Materials for High Performance Super...